05
Feb

A fledgling biotech in Norway’s notable cancer drug cluster has garnered about $12.5 million to back its early-stage efforts on a new therapy for acute myeloid leukemia and non-small cell lung cancer.

…read more

Source: Norway’s BerGenBio banks $12.5M for early-stage cancer drug R&D

    

0 No comments